Goldline Pharmaceutical's profit jumps 45% to ₹411.71 lacs in FY26
The nano-cap drugmaker's first full-year audited results show profit outpacing revenue growth. Revenue rose 11% to ₹3,119.76 lacs.
— 1 earlier story on Goldline Pharmaceutical Ltd. →What's new
- Net profit rose 45% to ₹411.71 lacs for the year ended March 31, 2026.
- Revenue grew 11% to ₹3,119.76 lacs.
- The board appointed an internal auditor alongside approving the results.
Why this matters
This is the first full-year audited result for Goldline, a recently listed nano-cap. The 45% profit jump on 11% revenue growth points to lower costs or better pricing. The unmodified auditor's report provides a clean baseline for a company still proving itself.
What we're watching
- Whether the profit surge holds in coming quarters or reflects one-off items.
- How the new internal auditor influences governance at this early stage.
- Growth trends from a small revenue base.
The full read
Goldline Pharmaceutical, a recently listed nano-cap, posted 45% profit growth in its first full-year audited results. Net profit hit ₹411.71 lacs for FY26, up from ₹283.43 lacs the prior year. Revenue grew 11% to ₹3,119.76 lacs, meaning the bottom line outpaced the top line by a wide margin. That points to improved profitability for the small drugmaker. The auditor's report is unmodified. The board also brought on an internal auditor, a standard governance move for a newly public company. The filing adds little beyond the numbers, but it sets a clean financial baseline for a company still proving itself to the market.
Questions answered
- What were Goldline Pharmaceutical's headline numbers?
- For FY26, the company reported a net profit of ₹411.71 lacs, a 45% increase from the prior year's ₹283.43 lacs. Revenue grew 11% to ₹3,119.76 lacs.
- Why did profit grow much faster than revenue?
- Net profit expanded 45% while revenue grew only 11%, which indicates improved profitability, likely from cost control or better margins on its sales.
- What did the board do besides approve results?
- Along with the financials, the board appointed an internal auditor for the company.
- Is this a significant event for the company?
- It establishes the first clean, audited full-year benchmark since Goldline's listing. The auditor's report is unmodified, adding credibility to the numbers.
Goldline Pharmaceutical Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on GOLDLINE →- 9 Jun 2026 · 6:56 PM IST Goldline Pharmaceutical's profit jumps 45% to ₹411.71 lacs in FY26
- 35d ago Goldline promoter lifts stake to 29.27% with open-market buy